HUTCHMED (NASDAQ:HCM) Sets New 1-Year Low – Here’s Why

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM)’s stock price hit a new 52-week low on Wednesday . The stock traded as low as $12.53 and last traded at $12.67, with a volume of 28148 shares traded. The stock had previously closed at $12.87.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on HCM shares. Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Jefferies Financial Group raised HUTCHMED to a “strong-buy” rating in a report on Monday, January 19th. Weiss Ratings lowered HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 1st. Finally, Bank of America decreased their price objective on HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $16.88.

HUTCHMED Trading Down 1.6%

The company has a 50 day moving average of $14.27 and a 200 day moving average of $14.46. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.96 and a quick ratio of 4.83.

HUTCHMED (NASDAQ:HCM) last announced its quarterly earnings results on Friday, March 6th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $2.50 by ($2.49). The company had revenue of $135.42 million during the quarter, compared to analyst estimates of $290.50 million. Research analysts expect that HUTCHMED will post 0.41 earnings per share for the current fiscal year.

Institutional Trading of HUTCHMED

Several institutional investors have recently bought and sold shares of HCM. Ameriprise Financial Inc. raised its position in shares of HUTCHMED by 4.7% during the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after acquiring an additional 698 shares during the last quarter. Bank of America Corp DE raised its position in shares of HUTCHMED by 5.9% during the third quarter. Bank of America Corp DE now owns 21,791 shares of the company’s stock worth $343,000 after acquiring an additional 1,209 shares during the last quarter. Crossmark Global Holdings Inc. raised its position in shares of HUTCHMED by 3.3% during the fourth quarter. Crossmark Global Holdings Inc. now owns 52,476 shares of the company’s stock worth $700,000 after acquiring an additional 1,680 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its position in shares of HUTCHMED by 12.1% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company’s stock worth $273,000 after acquiring an additional 1,873 shares during the last quarter. Finally, State Street Corp raised its position in shares of HUTCHMED by 1.2% during the fourth quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after acquiring an additional 3,801 shares during the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.